Limula’s Post

🙌 Way to go for our current project, Phire! (aka ATLyphe AG) Danielle Villars, Renier Myburgh and Maddalena Marconato, together with their team, are working on an antibody-enabled blood stem cell transplantation as an intervention to cure life-threatening diseases of the blood and immune system ➡ https://lnkd.in/edbyNpgM Currently supported by Wyss Zurich, they now also gained the support from our colleagues at USZ Health Innovation Hub 😊 More info about that below 👇 #ImmuneSystem #StemCellTransplantation #InnovativeTherapies #BiotechInnovation #HealthcareAdvancements #Biotechnology #FutureOfMedicine

Stalicla, founded in 2017, a precision neuro clinical stage company, has raised $80m with Novartis, Pitcted, Edmond de Rothschild, and SPRIM as shareholders. Preparing for a $65m Series C to support Phase 2 trials and advance its neuro precision pipeline. Meet STALICLA SA @ #Sachs_BEF More Info @ https://lnkd.in/d7zEuKym #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW

Newly announced this morning, 120M in funding was secured for Neurona Therapeutics. The California based-biotech focuses on regenerative neural cell therapy, and has its lead candidate NRTX-1001 in phase I/II trails for drug-resistant mesial temporal lobe epilepsy (MTLE). The funding will be used for continued development to include the use of the lead candidate for the treatment of Alzheimer’s disease.  The cell therapy includes human inhibitory GABAergic interneurons, though to impact the hyperactive neural networks that underly the onset of epileptic seizures. So far, data from the therapeutic candidate appear to be promising. In December of 2023,  the company reported positive data from the first two patients enrolled in the phase I/II study. 17 months into the study, the first patient went from a baseline seizure frequency of 32 seizures per month to zero focal impaired awareness seizures. The second patient had a baseline of 14 seizures per month and at the 12-month mark had not experienced any focal seizures within the last 6 months. Sources: Biospace, Neurona Therapeutics #celltherapy #biotechnology

Exciting news for healthcare innovation! 🌟 Washington University joins forces with Deerfield Management to launch VeritaScience, a cutting-edge R&D venture designed to transform scientific discoveries into life-saving therapies. With Deerfield's $130M backing over a decade, this initiative promises to accelerate drug development in critical areas like oncology, neurology, and more. Get the full scoop on how this academia-industry powerhouse will streamline the journey from lab to patient care. #VeritaScience #HealthcareInnovation #PartnershipPower #TherapeuticsDevelopment #WashingtonUniversity #DeerfieldManagement 🧬💊🔬

The reported findings from research conducted in collaboration with UT Southwestern Medical Center demonstrate the immune-enhancing, metastasis-reducing effects of MAIA’s telomere-targeting agent, THIO (6TdG), in several well-characterized in vitro and in vivo models of #SCLC. Read more here https://lnkd.in/dJC-v8pH #Biotech #Science #Oncology

Pleased to share our recent work with you: Boosting antitumor efficacy using docetaxel-loaded nanoplatforms: from cancer therapy to regenerative medicine approaches The intersection of nanotechnology and pharmacology has revolutionized the delivery and efficacy of chemotherapeutic agents, notably docetaxel, a key drug in cancer treatment. Traditionally limited by poor solubility and significant side effects, docetaxel’s therapeutic potential has been significantly enhanced through its incorporation into nanoplatforms, such as nanofibers and nanoparticles. This advancement offers targeted delivery, controlled release, and improved bioavailability, dramatically reducing systemic toxicity and enhancing patient outcomes. Read the full text here: https://lnkd.in/dY7SzgFm To participate in similar research studies, join the USERN Regenerative Medicine group | https://t.me/USERN_Remed #RegenerativeMedicine, #TissueEngineering, #Nanoplatforms, #Nanofibers, #Nanoparticles, #DocetaxelEncapsulation

Oct 4th already?! It’s that time of year for: - 🌍 World Animal Day - 🚀 The start of World Space Week - ☕ Kanelbullens Dag (Cinnamon Roll Day in #Sweden and #Finland) AAAAND… Pluripotency Day! Why is today special for stem cell research? ▶ Oct4 is a transcription factor crucial for regulating pluripotency in embryos and directing cell lineage commitment. ▶ It’s a key biomarker in Stem Cell and Cancer research. ▶ And, it's one of the Yamanaka factors used to create induced pluripotent stem cells (iPSCs). Learn more in our iPSC E-Book ➡️ https://lnkd.in/dXMWvRR2 #PluripotencyDay #OCT4 #stemcellresearch #pluripotent #ipsc #embryonicstemcells #reprogramming

On the healthcare front we have our second speaker from Nanoligent. Nanoligent is a Barcelona-based drug discovery company spun off from Universitat Autònoma de Barcelona and Institut de Recerca de l’Hopital. Nanoligent utilizes a platform technology based on modular design of targeted protein scaffold that can be targeted by various ligands and bound to different drugs. Nanoligent holds exclusive licenses for the family patents covering the protein-based nanomedicines platform in development, offering a first-in-class technological platform for a known validated target approach. The global market for Oncology/Cancer Drugs will expand from USD 146.72 billion to USD 311.81 billion over the next decade. Our Family is looking closely at their AI technology to take a view on this opportunity.   #UCEACapital #Nanoligent #investing #familyoffices #oncology #cancer #healthcare #London #protein

Adoram Therapeutics, a University of Geneva spin-off, is developing next-generation (allosteric) small molecule drugs, which are safer and more effective than conventional (orthosteric) small molecules. We have developed an allosteric screening platform to efficiently identify positive or negative modulators of GPCR drug targets. We are securing investments to progress two preclinical stage assets towards human trials, and to expand our pipeline. Meet Adoram Therapeutics @ #Sachs_ELSF More Info @ https://lnkd.in/dQWhKYkV #ELSF2024 #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #RisingStars #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #SachsSpringLifeSciencesWeek #SSLSW

#investment I We're proud to share that we have joined a $120M Series E round in Neurona Therapeutics co-led by Viking Global Investors and Cormorant Asset Management, LP  with participation from The Column Group along with additional new and existing investors 🎯 Groundbreaking #regenerative #CellTherapy for treatment of #drugresistant mesial temporal lobe #epilepsy 💼 Jordi Xiol 🔬 The candidate,NRTX-1001, is being evaluated in an ongoing open-label, single-arm Phase I/II clinical trial for the treatment of drug-resistant mesial temporal lobe #epilepsy (#MTLE) and has potential application in Alzheimer’s disease and other disorders of the nervous system. 💥 NRTX-1001 is a regenerative neural cell therapy candidate derived from human pluripotent #stemcells. The fully-differentiated neural cells, called interneurons, secrete the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). Delivered as a one-time dose, the human interneurons are intended to integrate on-target and durably silence #seizure activity in the epileptic region of the brain. #vc #biotech ##innovation #impactinvesting  #ClinicalTrial #GABAergicInterneuron